Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,531 shares of the medical equipment provider’s stock after selling 898 shares during the period. Mediolanum International Funds Ltd’s holdings in Hologic were worth $1,552,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Nilsine Partners LLC increased its position in Hologic by 3.3% in the fourth quarter. Nilsine Partners LLC now owns 42,876 shares of the medical equipment provider’s stock worth $3,091,000 after buying an additional 1,361 shares during the period. KBC Group NV grew its stake in shares of Hologic by 6.6% in the fourth quarter. KBC Group NV now owns 93,376 shares of the medical equipment provider’s stock worth $6,731,000 after purchasing an additional 5,747 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Hologic by 18.4% in the fourth quarter. Blue Trust Inc. now owns 8,428 shares of the medical equipment provider’s stock worth $608,000 after purchasing an additional 1,310 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Hologic by 11.4% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider’s stock worth $4,933,000 after purchasing an additional 6,986 shares in the last quarter. Finally, Olstein Capital Management L.P. grew its stake in shares of Hologic by 5.9% in the fourth quarter. Olstein Capital Management L.P. now owns 90,000 shares of the medical equipment provider’s stock worth $6,488,000 after purchasing an additional 5,000 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.88% of the company’s stock.

Hologic Trading Down 0.0 %

Shares of NASDAQ HOLX opened at $72.14 on Monday. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67. The company has a market cap of $16.28 billion, a price-to-earnings ratio of 21.66, a P/E/G ratio of 2.33 and a beta of 0.97. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $73.35 and a 200-day simple moving average of $78.07.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.89 EPS. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on HOLX shares. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Morgan Stanley decreased their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus price target of $88.92.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.